Pathogenesis of Corticotropic Tumors

[1]  J. Bertherat,et al.  Cushing's disease. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[2]  B. Meij,et al.  Cushing’s Disease in Dogs and Humans , 2009, Hormone Research in Paediatrics.

[3]  M. Malumbres,et al.  Cell cycle control of pituitary development and disease. , 2008, Journal of molecular endocrinology.

[4]  A. Grossman,et al.  Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. , 2008, Endocrine-related cancer.

[5]  K. Kovacs,et al.  p21Cip1 restrains pituitary tumor growth , 2008, Proceedings of the National Academy of Sciences.

[6]  J. Drouin,et al.  Regulatory Network Analyses Reveal Genome-Wide Potentiation of LIF Signaling by Glucocorticoids and Define an Innate Cell Defense Response , 2008, PLoS genetics.

[7]  K. Kovacs,et al.  Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. , 2007, Cancer research.

[8]  S. Bilodeau,et al.  Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency , 2007, Clinical genetics.

[9]  S. Melmed,et al.  Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. , 2007, Endocrine reviews.

[10]  Michael Buchfelder,et al.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. , 2007, European journal of endocrinology.

[11]  J. Bertherat,et al.  Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  D. Figarella-Branger,et al.  Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. , 2006, Genes & development.

[13]  K. Kovacs,et al.  Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. , 2005, Molecular endocrinology.

[14]  G. Camerino,et al.  Corticotroph adenoma of the pituitary in a patient with X-linked adrenal hypoplasia congenita due to a novel mutation of the DAX-1 gene. , 2005, European journal of endocrinology.

[15]  J. Bertherat,et al.  The Nelson's syndrome... revisited , 2005, Pituitary.

[16]  S. Asa,et al.  The 2004 World Health Organization classification of pituitary tumors: What is new? , 2005, Acta Neuropathologica.

[17]  R. Bronson,et al.  A dynamic switch in Rb+/− mediated neuroendocrine tumorigenesis , 2004, Oncogene.

[18]  C. A. Blake,et al.  Effects of corticotrophin-releasing hormone on corticotrophs in anterior pituitary gland allografts in hypophysectomized, orchidectomized hamsters , 1989, Cell and Tissue Research.

[19]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[20]  S. Czirják,et al.  Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  S. Melmed.  Mechanisms for pituitary tumorigenesis: the plastic pituitary. , 2003, The Journal of clinical investigation.

[22]  B. Scheithauer,et al.  Crooke's Cell Adenoma of the Pituitary: An Aggressive Variant of Corticotroph Adenoma , 2003, The American journal of surgical pathology.

[23]  X. Bertagna,et al.  Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. , 2003, European journal of endocrinology.

[24]  Joseph B. Rayman,et al.  E2F4 loss suppresses tumorigenesis in Rb mutant mice. , 2002, Cancer cell.

[25]  X. Bertagna,et al.  Overexpression of the V3 Vasopressin Receptor in Transgenic Mice Corticotropes Leads to Increased Basal Corticosterone , 2002, Journal of neuroendocrinology.

[26]  G. Sassolas,et al.  Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[28]  V. Godfrey,et al.  Functional Collaboration between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity , 2000, Molecular and Cellular Biology.

[29]  S. Melmed,et al.  Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. , 2000, Endocrine reviews.

[30]  J. Doppman,et al.  Extrapituitary parasellar microadenoma in Cushing's disease. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  C. Cordon-Cardo,et al.  p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Fahlbusch,et al.  Expression of menin gene mRNA in pituitary tumours. , 1999, European journal of endocrinology.

[33]  P. Dahia,et al.  The molecular pathogenesis of corticotroph tumors. , 1999, Endocrine reviews.

[34]  J. Rutka,et al.  Molecular Pathogenesis of Pituitary Adenomas: A Review , 1999, Acta Neurochirurgica.

[35]  C. Readhead,et al.  Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. , 1998, Molecular endocrinology.

[36]  V. Godfrey,et al.  CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. , 1998, Genes & development.

[37]  E. Gundelfinger,et al.  Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[38]  S. Asa,et al.  The MEN-1 gene is rarely down-regulated in pituitary adenomas. , 1998, The Journal of clinical endocrinology and metabolism.

[39]  T. Jacks,et al.  p21 Is a Critical CDK2 Regulator Essential for Proliferation Control in Rb-deficient Cells , 1998, The Journal of cell biology.

[40]  T. Jacks,et al.  Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/−) mice , 1998, Nature Genetics.

[41]  S. Lamberts,et al.  Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. , 1998, The Journal of clinical endocrinology and metabolism.

[42]  D. Grobbee,et al.  A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.

[43]  R. Fahlbusch,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Glucocorticoid Receptor Gene Isoforms in Corticotropin-Secreting Tumors* , 2022 .

[44]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[45]  James M. Roberts,et al.  A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 Kip1 -Deficient Mice , 1996, Cell.

[46]  K. Manova-Todorova,et al.  Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1 , 1996, Cell.

[47]  R. Fahlbusch,et al.  Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. , 1996, The Journal of clinical endocrinology and metabolism.

[48]  T. Mindermann,et al.  Age‐related and gender‐related occurrence of pituitary adenomas , 1994, Clinical endocrinology.

[49]  R. G. Allen,et al.  Post-translational processing of proopiomelanocortin (POMC) in mouse pituitary melanotroph tumors induced by a POMC-simian virus 40 large T antigen transgene. , 1993, The Journal of biological chemistry.

[50]  K. Kovacs.  The pathology of cushing's disease , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  X. Bertagna.  Unrestrained production of proopiomelanocortin (POMC) and its peptide fragments by pituitary corticotroph adenomas in Cushing's disease , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  A. Berns,et al.  Requirement for a functional Rb-1 gene in murine development , 1992, Nature.

[53]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[54]  A. Bradley,et al.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.

[55]  J. Vaughan,et al.  Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. , 1992, Endocrinology.

[56]  G. Siegal,et al.  Transgenic mice that develop pituitary tumors. A model for Cushing's disease. , 1992, The American journal of pathology.

[57]  K. Kovacs,et al.  Clonal origin of pituitary adenomas. , 1990, The Journal of clinical endocrinology and metabolism.

[58]  A. Arnold,et al.  Clinically nonfunctioning pituitary tumors are monoclonal in origin. , 1990, The Journal of clinical investigation.

[59]  B. Scheithauer,et al.  Tumors of the Pituitary Gland , 1990 .

[60]  T. Suda,et al.  Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro. , 1988, The Journal of clinical investigation.

[61]  D. Hanahan,et al.  Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene , 1987, Cell.

[62]  K. Kovacs,et al.  Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. , 1987, Endocrinology.

[63]  X. Bertagna,et al.  Altered proopiomelanocortin gene expression in adrenocorticotropin-producing nonpituitary tumors. Comparative studies with corticotropic adenomas and normal pituitaries. , 1985, The Journal of clinical investigation.

[64]  R. Fahlbusch,et al.  OVINE CORTICOTROPHIN RELEASING FACTOR STIMULATES ACTH RELEASE FROM HUMAN CORTICOTROPHINOMA CELLS IN CULTURE; INTERACTION WITH HYDROCORTISONE AND ARGININE VASOPRESSIN , 1985, Clinical endocrinology.

[65]  V. Challa,et al.  Pathobiologic study of pituitary tumors: report of 62 cases with a review of the recent literature. , 1985, Human pathology.

[66]  W. Burch.  Cushing's disease. A review. , 1985, Archives of internal medicine.

[67]  S. Lamberts,et al.  Studies on the glucocorticoid-receptor blocking action of RU 38486 in cultured ACTH-secreting human pituitary tumour cells and normal rat pituitary cells. , 1985, Acta endocrinologica.

[68]  K. Westlund,et al.  Quantification of morphological changes in pituitary corticotropes produced by in vivo corticotropin-releasing factor stimulation and adrenalectomy. , 1985, Endocrinology.

[69]  S. Lamberts,et al.  ACTH and beta-endorphin secretion by three corticotrophic adenomas in culture. Effects of culture time, dexamethasone, vasopressin and synthetic corticotrophin releasing factor. , 1984, Acta endocrinologica.

[70]  W. Vale,et al.  Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor. , 1982, The Journal of clinical endocrinology and metabolism.

[71]  W. Nicholson,et al.  Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. , 1982, Endocrinology.

[72]  W. Nicholson,et al.  Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses. , 1982, Endocrinology.

[73]  W. Priester,et al.  Epidemiological aspects of clinical hyperadrenocorticism in dogs (canine Cushing's syndrome). , 1982 .

[74]  D. Krieger,et al.  Pituitary intermediate lobe in dog: two cell types and high bioactive adrenocorticotropin content. , 1981, Science.

[75]  A. Grossman,et al.  SECRETION OF ACTH, LPH AND β‐ENDORPHIN FROM HUMAN PITUITARY TUMOURS IN VITRO , 1980 .

[76]  G. Gillies,et al.  Adrenocorticotropin and lipotropin secretion by dispersed cell cultures of a human corticotropic adenoma: effect of hypothalamic extract, arginine vasopressin, hydrocortisone, and serotonin. , 1980, The Journal of clinical endocrinology and metabolism.

[77]  J. Klijn,et al.  The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. , 1980, The Journal of clinical endocrinology and metabolism.

[78]  W. Odell,et al.  THE DOSE‐RESPONSE RELATIONSHIP OF ACTH AND CORTISOL IN CUSHING'S DISEASE , 1980, Clinical endocrinology.

[79]  S. Lamberts,et al.  Failure of clinical remission after transsphenoidal removal of a microadenoma in a patient with Cushing's disease: multiple hyperplastic and adenomatous cell nets in surrounding pituitary tissue. , 1980, The Journal of clinical endocrinology and metabolism.